Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical technology platform company specializing in innovative drug delivery solutions. The company focuses on enhancing the administration of biologic and other injectable therapies through its proprietary ENHANZE drug delivery technology, built on the recombinant human hyaluronidase enzyme rHuPH20. This platform enables subcutaneous delivery of medicines that are traditionally given intravenously, aiming to reduce treatment time and ease the burden on patients across oncology and other therapeutic areas. Halozyme Therapeutics also develops, manufactures, and commercializes drug-device combination products that use advanced auto-injector technologies to improve convenience, reliability, and tolerability. Its current product portfolio includes Hylenex recombinant, a formulation of rHuPH20 used to facilitate subcutaneous fluid and drug administration, and XYOSTED, a subcutaneous auto-injector for testosterone replacement therapy. The company operates a hybrid model of proprietary products and partnered programs, licensing its technology to major pharmaceutical companies to support the delivery of emerging and established therapies. Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics today plays a notable role in the global biotechnology and specialty pharmaceuticals market.